Agnieszka Witkiewicz

Professor of Pathology and Oncology

Roswell Park Comprehensive Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (23)

Pancreatic ductal adenocarcinoma (PDAC) is an exceedingly lethal cancer that lacks actionable molecular drivers, limiting precision treatment options. We previously identified the transcription factor, HNF1A, as a novel driver of tumorigenesis and pancreatic cancer stem cell (PCSC) properties in PDAC; however, HNF1A-targeting modalities do not currently exist. Here we show that HNF1A is a direct target of the epigenetic reader protein, BRD4, and its expression is exquisitely sensitive to BET-inhibitors (BETi), which inhibit PDAC cell proliferation and block PCSC-properties in a panel of HNF1A-expressing cell lines and patient-derived xenograft cells. Remarkably, we report that the antineoplastic activity of BETi/BRD4 knockdown can be overcome by restoration of HNF1A expression, but not by re-expression of canonical BETi target MYC. RNA-sequencing analyses revealed that a subset of BETi-responsive transcripts is dependent on HNF1A expression, including receptor tyrosine kinases (RTKs), regulators and ligands. Consistent with these data, we found that HNF1A restoration rescued EGFR/ERBB3-signaling and the protective effects of HNF1A restoration could be overcome with EGFR-inhibitors. Furthermore, we found that expressions of HNF1A, BRD4, and ERBB3 were strongly correlated across PDAC patient samples using multispectral immunofluorescence, supporting a connection between these players in PDAC biology, and high expression of ERBB3 associated with better survival, supporting the clinical importance of this network in patient outcomes. These findings demonstrate that BETi can be used to ablate HNF1A expression and that the inhibition of HNF1A is critical for BETi activity, while supporting HNF1A as novel therapeutic target in PDAC. Significance This study demonstrates that the oncogenic transcription factor HNF1A is a direct target of BRD4, and that the ablation of HNF1A by BET-inhibitors is central to their antineoplastic activity in PDAC.

Year:

2025

Figure S2. Contextual biochemical response to CDK inhibition. A, Western blot of RB1-E2F pathway activity in OVSAHO and MDA-MB-157 cells following BLU-222 or palbociclib treatment. B, Schematic depicting mVenus-DHB and mCherry-RB CDK activity reporter constructs. C, Representative images of mCherry-RB sensor activity in OVCAR-3 and T-47D cells treated with 500 nM BLU-222 or palbociclib (scale bar = 100 µm). D, Quantification of mCherry-RB CDK activity sensor localization to the cytosol or nucleus in the indicated ovarian and breast cancer cell lines following treatment with either 500 nM BLU-222 or palbociclib. E, Representative images of mCherry-RB sensor activity in OVCAR-3 cells transfected with si NT , si CCNE1 or si CCND1 (scale bar = 100 µm). F, Quantification of mCherry-RB CDK activity sensor localization to the cytosol or nucleus in OVCAR-3 and MDA-MB-157 cells following knockdown of CCNE1 or CCND1 with siRNA constructs.

Year:

2025

Figure S6. P16INK4A is a key determinant of response to BLU-222. A, Heatmap analysis from the cancer dependency map (DepMap) database displaying relative expression of CCNE1 and several endogenous CDK inhibitor genes in a panel of established ovarian and breast cancer cell lines. B, Western blot of RB1-E2F pathway activity in MDA-MB-157 cells following overexpression (OE) of CDK4 with and without BLU-222 treatment. C, Live cell proliferative monitoring of CDK4 WT (left) and overexpressing (OE, right) of MDA-MB-157 cells treated with serial concentrations of BLU-222 [n = 3–4 per group; two-way ANOVA, significance (shown as #) comparing CDK4 OE versus CDK4 WT at 62.5 nM BLU-222 dose; error bars represent SEM]. D, Western blot of RB1-E2F pathway activity in MDA-MB-157 cells following overexpression (OE) of CDK6 with and without BLU-222 treatment. E, Live cell proliferative monitoring of CDK6 WT (left) and overexpressing (OE, right) MDA-MB-157 cells treated with serial concentrations of BLU-222 [n = 3–4 per group; two-way ANOVA, significance (shown as #) comparing CDK6 OE versus CDK6 WT at 250 nM BLU-222 dose; error bars represent SEM]. F, Table summarizing effect of CDK4 or CDK6 overexpression (OE) or CDKN2A knockdown on IC50 to BLU-222 in Kuramochi and MDA-MB-157 cells. G, Hematoxylin and Eosin (H&E) staining and of tumors excised from MDA-MB-157 xenografts in NOD scid gamma (NSG) mice treated with either vehicle or BLU-222; arrows indicate cells with enlarged morphology (scale bar = 100 µm). #, P

Year:

2025

Cyclin-dependent kinase 2 (CDK2) inhibitors have recently been developed and have entered clinical trials. Combination approaches can help broaden the use of therapeutic agents and establish more effective treatments. Here, we evaluated the selective CDK2 inhibitor BLU-222 for mechanisms of response in the context of ovarian and breast cancer models. Sensors of cellular CDK activity indicated that sensitivity to either CDK4/6 or CDK2 inhibition was related to the differential dependence on a single CDK for G 1 –S transition. Unlike CDK4/6 inhibitors, BLU-222 was able to robustly inhibit proliferation through cell-cycle inhibition in both G 1 and G 2 phases. However, it remained possible for cells to reenter the cell cycle upon drug withdrawal. The antiproliferative strength and impact on G 1 –S versus G 2 –M accumulation was mediated by the RB tumor suppressor. To broaden the sensitivity to CDK2 inhibition, combinatorial drug screens were performed that identified both synergistic (e.g., CDK4/6 inhibitors) and antagonistic (e.g., WEE1 inhibitors) relationships. Models that were exceptionally sensitive to CDK2 inhibition displayed coordinate expression of cyclin E1 and P16 INK4A , an endogenous CDK4/6 inhibitor. Functional studies demonstrated that P16 INK4A and CDK4/6 activity were key mediators of sensitivity to BLU-222. Clinical gene and protein expression analyses revealed a positive correlation between cyclin E1 and P16 INK4A and identified that ∼25% of ovarian cancers exhibited coordinate expression of cyclin E, P16 INK4A , and RB, indicative of strong sensitivity to CDK2 inhibition. Together, this work advances a precision strategy for the use of CDK2 inhibitors in the context of ovarian and breast cancers. Significance: The CDK2-specific inhibitor BLU-222 shows preclinical efficacy in breast and ovarian cancer with select determinants of response and holds promise in combinatorial strategies. See related article by House and colleagues, p. 1297

Year:

2025

Figure S5. Cooperative and antagonistic combination strategies with BLU-222. A, BLISS synergistic analysis for antagonism between BLU-222 and CHK1 checkpoint kinase inhibitors in MDA-MB-231 cells (n = 3 per group; BLISS scores calculated with SynergyFinder v3). B, Live cell proliferative monitoring of the indicated cell lines treated with BLU-222, palbociclib, or in combination (n = 3–4 per group; one-way ANOVA; error bars represent SEM). C, Quantification of mVenus-DHB and mCherry-RB CDK activity sensor localization to the cytosol or nucleus in MDA-MB-231 and HCC-1806 cells following treatment with either 500 nM BLU-222, palbociclib, or combination. D, Quantification of mVenus-DHB and mCherry-RB CDK activity sensor localization to the cytosol or nucleus in MDA-MB-231 and HCC-1806 cells following treatment with si CCNE1 , si CCND1 or combination. E, Live-cell imaging endpoint stills for HCC-1806 cells treated for 5 days with 500 nM BLU-222, palbociclib, or combination (scale bar = 100 µm). ns, not significant; *, P

Year:

2025

Figure S4. Loss of RB1 shifts phase of arrest and sensitivity to BLU-222. A, Heatmap of RNA sequencing data comparing differential gene expression between BLU-222-treated Kuramochi (125 nM BLU-222) and OVCAR-8 (250 nM BLU-222) cells normalized to respective DMSO-treated controls. B, Cell cycle profiling from univariate flow cytometric analysis from OVCAR-8 cells at baseline, after 1 to 5 days of treatment with 500 nM BLU-222, and after 1 to 5 days of drug washout. C, Western blot for abrogation of G2/M checkpoint signaling in OVCAR-8 cells following doxycycline (Dox) induction of the RB1 expression vector and treatment with BLU-222 compared with RB1 deficient controls. D, Live cell proliferative monitoring of OVCAR-8 cells following Dox induction of the RB1 expression vector (RB1 Dox +) with non-induced controls (RB1 Dox -) and treatment with serial concentrations of palbociclib (n = 3–4 per group; error bars represent SEM). E, Table summarizing effect of RB1 induction on IC50 to BLU-222 in OVCAR-8 cells. F, Live cell proliferative monitoring of OVCAR-8 cells following doxycycline induction of the RB1 expression vector (RB1 Dox +) with non-induced controls (RB1 Dox -) and transfection with si NT , si CCNE1 , or si CCNA2 [n = 3–4 per group; two-way ANOVA, significance (shown as #) for combined RB1 and siRNA effect; error bars represent SEM]. G, Live-cell imaging endpoint stills for the OVCAR-8 cells in D (scale bar = 100 µm). H, Western blot of RB1-E2F pathway activity in Kuramochi cells with RB1 knockdown or si NT control and treatment with BLU-222. I, Cell cycle profiling from univariate flow cytometric analysis from Kuramochi cells with RB1 knockdown or si NT control and treatment with BLU-222. J, Western blot of RB1-E2F pathway activity in MDA-MB-157 cells with and without deletion (DEL) of RB1 and treatment with BLU-222. K, Cell cycle profiling from univariate flow cytometric analysis from MDA-MB-157 cells with and without deletion (DEL) of RB1 and treatment with BLU-222. L, Table summarizing effect of RB1 knockdown/deletion on IC50 to BLU-222 in Kuramochi and MDA-MB-157 cells, respectively. ####, P

Year:

2025

Supplemental File 1. BLU-222 combinatorial drug screen data from MDA-MB-231 (tab 1) and COV-504 cells (tab 2) reported in Figure 5. Data reported as percent growth compared to sole treatment with 0.1% DMSO.

Year:

2025

Figure S3. BLU-222 elicits potent G1 arrest in Cyclin E1 and P16INK4A-high models expressing RB. A, Cell cycle profiling from univariate flow cytometric analysis from the indicated cell lines following treatment with palbociclib. B, Bivariate flow cytometric analysis from the indicated cell lines following transfection with si NT or si CCNE1 constructs. C, RNA sequencing gene set enrichment plots for E2F targets and interferon alpha response pathways in Kuramochi and MDA-MB-157 cells following treatment with 125 nM BLU-222 or 100 nM, respectively, for 48 hours compared to DMSO-treated controls. PI, propidium iodide; FITC, anti-bromodeoxyuridine fluorescein.

Year:

2025

Figure S7. Prevalence of Cyclin E1-P16INK4A high tumors that express RB. A, Kaplan Meier curves based on CCNE1 status generated from The Cancer Genome Atlas (TCGA) serous ovarian carcinoma database. HR, hazard ratio; DFS, disease-free survival; OS, overall survival. Amp, amplification. B, Oncoprint of the serous ovarian carcinoma TCGA database for the indicated cell cycle genes. C, Normalized intensity for Cyclin D1, Cyclin E1, or P16INK4A expression within clusters 1, 3, and 4 (n = 82002 for cluster 1, n = 150037 for cluster 3, and n = 34088 for cluster 4; unpaired t-test between clusters 1 and 4). D, SCIMAP analysis of unique spatial single cell protein expression signatures of all 159 cores from the patient-derived gynecological tumor microarray (TMA). E, Computational algorithm-based identification of Cyclin E1 high /P16 high /RB + cores from the gynecological TMA expected to be sensitive to CDK2 inhibition.

Year:

2025

Differential vulnerabilities to CDK2 versus CDK4/6 inhibition. A, Table of top identified predictive genes in breast and ovarian carcinomas for response to CDK2 inhibition from the publicly available DepMap dataset using CRISPR (top) and RNAi (bottom) screens. B, Cell Titer Glo values normalized to 0 nM treatment of ovarian and breast cancer cells treated with BLU-222 for 5 days. C, Table summarizing breast and ovarian cancer cell line response to BLU-222 treatment. D, COV-504 and PE-O1 ovarian cancer cell lines treated with serial concentrations of BLU-222 or palbociclib for 5 days and monitored with Cellcyte or Incucyte live cell proliferative software (n = 3–4 per group; error bars represent SEM).

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (12)

Sheila Stewart

Professor

Washington University in St. Louis

UNITED STATES
View details

Michael Feigin

Assistant Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Scott Powers

Professor

Stony Brook University

UNITED STATES
View details

Erik Knudsen

Chairperson/Associate Director of Basic Science

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Mark Long

Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Katerina Gurova

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

David G. DeNardo

Professor of Medicine

Washington University School of Medicine

UNITED STATES
View details

Karen McLean

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Prasenjit Dey

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Ethan Abel

Associate Member/Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Deborah Novack

Professor

Washington University in St. Louis

UNITED STATES
View details

Gregory Longmore

Professor

Washington University in St. Louis

UNITED STATES
View details